利妥昔-话题@MedSci

#利妥昔#

179篇内容 | 3541人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1660473, encodeId=194316604e353, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期, objectType=article, longId=176195, objectId=60091e619534, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60091e619534, replyNumber=0, likeNumber=66, createdTime=2019-09-24, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60091e619534, moduleTitle=Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60091e619534)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660469, encodeId=e1a41660469e5, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Rheumatol：利妥昔单抗治疗系统性类风湿性血管炎, objectType=article, longId=174425, objectId=bc161e442595, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc161e442595, replyNumber=0, likeNumber=57, createdTime=2020-02-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc161e442595, moduleTitle=J Rheumatol：利妥昔单抗治疗系统性类风湿性血管炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc161e442595)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660486, encodeId=770a166048626, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准, objectType=article, longId=191492, objectId=9a9c19149256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a9c19149256, replyNumber=0, likeNumber=119, createdTime=2020-06-10, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a9c19149256, moduleTitle=辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a9c19149256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660475, encodeId=feab16604e50e, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=FDA批准利妥昔单抗联合类固醇激素治疗儿童血管炎, objectType=article, longId=180296, objectId=f9a2180296ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9a2180296ef, replyNumber=0, likeNumber=69, createdTime=2020-06-26, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9a2180296ef, moduleTitle=FDA批准利妥昔单抗联合类固醇激素治疗儿童血管炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9a2180296ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660483, encodeId=285d166048342, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Rheumatol：与利妥昔单抗相关的血管炎急性发作 , objectType=article, longId=190386, objectId=1760190386ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1760190386ea, replyNumber=0, likeNumber=50, createdTime=2020-08-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1760190386ea, moduleTitle=J Rheumatol：与利妥昔单抗相关的血管炎急性发作 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1760190386ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660476, encodeId=fe0d16604e614, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JAMA Neurol：利妥昔单抗、那他珠单抗、芬戈莫德治疗MS感染风险差异研究, objectType=article, longId=181171, objectId=ed4e1811e104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed4e1811e104, replyNumber=0, likeNumber=117, createdTime=2020-02-27, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed4e1811e104, moduleTitle=JAMA Neurol：利妥昔单抗、那他珠单抗、芬戈莫德治疗MS感染风险差异研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed4e1811e104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660461, encodeId=997d166046118, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=国产生物类似药利妥昔单抗获批上市, objectType=article, longId=161099, objectId=2fe916109976, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fe916109976, replyNumber=0, likeNumber=111, createdTime=2019-08-29, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fe916109976, moduleTitle=国产生物类似药利妥昔单抗获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fe916109976)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660466, encodeId=1c9d16604665b, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Arthritis Rheumatol：利妥昔单抗作为系统性红斑狼疮维持治疗的观察性研究, objectType=article, longId=166546, objectId=132e16654688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=132e16654688, replyNumber=0, likeNumber=77, createdTime=2019-08-01, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=132e16654688, moduleTitle=Arthritis Rheumatol：利妥昔单抗作为系统性红斑狼疮维持治疗的观察性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=132e16654688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660474, encodeId=17f016604e40c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：伊布替尼-利妥昔单抗治疗慢性淋巴细胞白血病, objectType=article, longId=176645, objectId=15ff1e664561, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15ff1e664561, replyNumber=0, likeNumber=50, createdTime=2020-05-10, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15ff1e664561, moduleTitle=NEJM：伊布替尼-利妥昔单抗治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15ff1e664561)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660470, encodeId=be3a16604e03a, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=NEJM：利妥昔单抗或环孢素治疗膜性肾病的疗效比较, objectType=article, longId=174797, objectId=ebe11e4797ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ebe11e4797ee, replyNumber=0, likeNumber=75, createdTime=2020-02-12, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ebe11e4797ee, moduleTitle=NEJM：利妥昔单抗或环孢素治疗膜性肾病的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ebe11e4797ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660477, encodeId=540c16604e731, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功, objectType=article, longId=181544, objectId=65631815442f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65631815442f, replyNumber=0, likeNumber=66, createdTime=2020-03-14, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65631815442f, moduleTitle=罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65631815442f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660478, encodeId=c52016604e862, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=J Rheumatol：使用利妥昔单抗治疗全身性类风湿性血管炎, objectType=article, longId=183654, objectId=e3b318365420, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3b318365420, replyNumber=0, likeNumber=79, createdTime=2020-05-17, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3b318365420, moduleTitle=J Rheumatol：使用利妥昔单抗治疗全身性类风湿性血管炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3b318365420)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660456, encodeId=bc6f16604564c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=CLIN CANCER RES：Alisertib联合利妥昔单抗或利妥昔单抗/长春新碱治疗B细胞淋巴瘤, objectType=article, longId=156279, objectId=a9f81562e9c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9f81562e9c5, replyNumber=0, likeNumber=68, createdTime=2019-04-03, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9f81562e9c5, moduleTitle=CLIN CANCER RES：Alisertib联合利妥昔单抗或利妥昔单抗/长春新碱治疗B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9f81562e9c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660463, encodeId=16c816604635c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Ann Rheum Dis：当代实践中使用利妥昔单抗治疗系统性硬化症的结局, objectType=article, longId=164013, objectId=51ed16401381, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51ed16401381, replyNumber=0, likeNumber=88, createdTime=2020-02-13, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51ed16401381, moduleTitle=Ann Rheum Dis：当代实践中使用利妥昔单抗治疗系统性硬化症的结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51ed16401381)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660462, encodeId=15d216604629c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=国产生物类似药利妥昔单抗获批上市！, objectType=article, longId=161236, objectId=e750161236b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e750161236b8, replyNumber=0, likeNumber=59, createdTime=2019-03-28, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e750161236b8, moduleTitle=国产生物类似药利妥昔单抗获批上市！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e750161236b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660458, encodeId=b28816604582f, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Neurology：进展型多发性硬化：鞘内注射利妥昔单抗是否安全可行？, objectType=article, longId=156989, objectId=ed3a15698959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed3a15698959, replyNumber=0, likeNumber=61, createdTime=2019-09-08, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed3a15698959, moduleTitle=Neurology：进展型多发性硬化：鞘内注射利妥昔单抗是否安全可行？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed3a15698959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660457, encodeId=68ee166045ef5, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Rheumatology (Oxford)：早期弥漫性硬皮肺病：利妥昔单抗vs环磷酰胺, objectType=article, longId=156515, objectId=c224156515b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c224156515b3, replyNumber=0, likeNumber=73, createdTime=2019-05-27, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c224156515b3, moduleTitle=Rheumatology (Oxford)：早期弥漫性硬皮肺病：利妥昔单抗vs环磷酰胺, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c224156515b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660467, encodeId=7f61166046e69, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Arthritis Rheumatol：预测利妥昔单抗治疗风湿和肌肉骨骼疾病期间严重感染和低丙种球蛋白血症的影响, objectType=article, longId=167198, objectId=c50b16e198b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c50b16e198b7, replyNumber=0, likeNumber=55, createdTime=2020-01-02, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c50b16e198b7, moduleTitle=Arthritis Rheumatol：预测利妥昔单抗治疗风湿和肌肉骨骼疾病期间严重感染和低丙种球蛋白血症的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c50b16e198b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660471, encodeId=85a516604e14c, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=Blood：滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险, objectType=article, longId=175624, objectId=7de11e562462, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7de11e562462, replyNumber=0, likeNumber=74, createdTime=2020-01-05, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7de11e562462, moduleTitle=Blood：滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7de11e562462)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1660472, encodeId=f4a216604e24d, content=<a href='/topic/show?id=c0de32285a1' target=_blank style='color:#2F92EE;'>#利妥昔#</a>, objectTitle=JACC：利妥昔单抗可增加心脏移植术后患者移植物血管病变, objectType=article, longId=175845, objectId=03691e5845ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03691e5845ae, replyNumber=0, likeNumber=66, createdTime=2020-02-19, rootId=0, userName=花花1374, userId=a58d25117340, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03691e5845ae, moduleTitle=JACC：利妥昔单抗可增加心脏移植术后患者移植物血管病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03691e5845ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利妥昔

2020-05-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：依鲁替尼联合来那度胺和利妥昔单抗用于复发性/难治性非生发中心B细胞DLBCL的疗效可期

2019-09-24

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Rheumatol：利妥昔单抗治疗系统性类风湿性血管炎

2020-02-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

辉瑞的美罗华（利妥昔单抗）仿制药Ruxience，获得欧盟批准

2020-06-10

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

FDA批准利妥昔单抗联合类固醇激素治疗儿童血管炎

2020-06-26

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Rheumatol：与利妥昔单抗相关的血管炎急性发作

2020-08-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JAMA Neurol：利妥昔单抗、那他珠单抗、芬戈莫德治疗MS感染风险差异研究

2020-02-27

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

国产生物类似药利妥昔单抗获批上市

2019-08-29

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Arthritis Rheumatol：利妥昔单抗作为系统性红斑狼疮维持治疗的观察性研究

2019-08-01

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：伊布替尼-利妥昔单抗治疗慢性淋巴细胞白血病

2020-05-10

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

NEJM：利妥昔单抗或环孢素治疗膜性肾病的疗效比较

2020-02-12

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

罗氏CD20利妥昔单抗治疗寻常型天疱疮的III试验成功

2020-03-14

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

J Rheumatol：使用利妥昔单抗治疗全身性类风湿性血管炎

2020-05-17

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

CLIN CANCER RES：Alisertib联合利妥昔单抗或利妥昔单抗/长春新碱治疗B细胞淋巴瘤

2019-04-03

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Ann Rheum Dis：当代实践中使用利妥昔单抗治疗系统性硬化症的结局

2020-02-13

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

国产生物类似药利妥昔单抗获批上市！

2019-03-28

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Neurology：进展型多发性硬化：鞘内注射利妥昔单抗是否安全可行？

2019-09-08

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Rheumatology (Oxford)：早期弥漫性硬皮肺病：利妥昔单抗vs环磷酰胺

2019-05-27

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Arthritis Rheumatol：预测利妥昔单抗治疗风湿和肌肉骨骼疾病期间严重感染和低丙种球蛋白血症的影响

2020-01-02

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

Blood：滤泡性淋巴瘤采用本达莫司汀联合利妥昔单抗治疗后早期病程进展提示高转化风险

2020-01-05

花花1374 (审核中...)

前往app查看评论内容

#利妥昔#

JACC：利妥昔单抗可增加心脏移植术后患者移植物血管病变

2020-02-19

科室
- - 订阅+
  - 更多科室
工具
服务